In a banner year for biopharma, here are the best industry CEOs of 2025

Taking stock of the drug industry, from the lab to the medicine chest

December 16, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Hyacinth Empinado/STAT STAT+ | In a banner year for biopharma, here are the best industry CEOs of 2025 STAT's Adam Feuerstein notes that, in a banner year for biopharma, there were dealmakers, underdogs, and even a maverick. By Adam Feuerstein STAT+ | Ambros Therapeutics, Ramaswamy's latest startup, launches with plans for pain treatment Vivek Ramaswamy'a latest startup will develop and test a new treatment for Complex Regional Pain Syndrome. By Allison DeAngelis Opinion: We crunched the numbers on drug discovery in the U.S. vs. China. The results were alarming Federal policy and priorities are kneecapping the historical American engines of innovation, to China's benefit. By Michael Kinch and Kevin Gardner

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser